CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals

A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most co...
Continue Reading →
News

Late cancer diagnoses rise as NHS struggles with COVID-19

Analyses provided by UK cancer charity Macmillan has provided insights into the repercussions experienced by patients waiting to receive treatment during the COVID-1...
Continue Reading →
News

NICE does not recommend tucatinib for advanced breast cancer

NICE has published draft guidance for public consultation which does not recommend tucatinib, in combination with trastuzumab and capecitabine, for some types of bre...
Continue Reading →
News

UK trial to evaluate existing drugs for secondary breast cancer

A new UK-based clinical trial will evaluate existing cancer drugs as potential treatments for women living with metastatic breast cancer. The study, led by Profes...
Continue Reading →
News

Roche withdraws US approval for Tecentriq in mTNBC

Roche has voluntarily withdrawn its US accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for the treatment of adults with unresectab...
Continue Reading →
News

Enhertu improves progression-free survival in breast cancer trial

Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conju...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026